Evidence map›Paper›PMID 41651961›Full record

Trial reportScientific reports2026

Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials.

Ahmad Y Abuhelwa, Sara A Almansour, Humaid O Al-Shamsi, Ziad Abuhelwa, Mohammad A Y Alqudah, Yasser Bustanji, Mohammad H Semreen, Karem H Alzoubi, Natansh D Modi, Ross A McKinnon and 2 more

Abstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ahmad Y AbuhelwaCollege of Pharmacy, University of Sharjah, Sharjah, UAE. Ahmad.Abuhelwa@sharjah.ac.ae.
Sara A AlmansourCollege of Pharmacy, University of Sharjah, Sharjah, UAE.
Humaid O Al-ShamsiDepartment of Oncology, Burjeel Cancer Institute, Burjeel Medical City, P.O. Box 92510, Abu Dhabi, UAE.
Ziad AbuhelwaDepartment of Hematology and Medical Oncology, University of South Florida/ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Mohammad A Y AlqudahCollege of Pharmacy, University of Sharjah, Sharjah, UAE.
Yasser BustanjiCollege of Medicine, University of Sharjah, Sharjah, UAE.
Mohammad H SemreenCollege of Pharmacy, University of Sharjah, Sharjah, UAE.
Karem H AlzoubiCollege of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Natansh D ModiClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Ross A McKinnonCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Michael J SorichCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Ashley M HopkinsCollege of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.

Funding

Tour De Cure Research Grant RSP-117-FY2023University of Sharjah Targeted Grant 2301110392
6 · The paper itself

Abstract

Patients with multiple myeloma (MM) often use cardiovascular medications due to their increased risk of cardiovascular diseases. This study investigated the associations of baseline use of these drugs with survival and adverse events in MM patients initiating daratumumab, lenalidomide, or bortezomib combination treatments. Data from Phase III trials (CASTOR, MAIA, and POLLUX) were analysed, focusing on beta-blockers, calcium channel blockers, ACE inhibitors (ACEI), angiotensin II receptor blockers (ARBs), diuretics, and statins. Cox proportional hazard analysis and logistic regression were used to assess associations with survival and grade ≥ 3 adverse events. Among 1804 patients, ACEI/ARBs were most common (31%), followed by beta-blockers (23%), statins (21%), calcium channel blockers (17%), and diuretics (16%). ACEI/ARBs was associated with better progression-free survival (adjusted hazard ratio (aHR) [95% CI] = 0.84 [0.71-0.99], P = 0.034) but also higher odds of grade ≥ 3 adverse events (adjusted odds ratio (aOR) = 1.45 [1.06-1.97], P = 0.019). Diuretics were similarly associated with grade ≥ 3 adverse events (aOR = 1.53 [1.01-2.34], P = 0.047). Other cardiovascular drugs showed no significant associations. While ACEI/ARBs may improve progression-free survival, they pose safety concerns. It is reassuring that other cardiovascular drugs were not significantly associated with MM treatment outcomes. Further research is essential to fully understand the implications of these medications.

Indexed as

Cardiovascular AgentsCardiovascular DiseasesMultiple MyelomaAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibCalcium Channel BlockersClinical Trials, Phase III as TopicFemaleHumansLenalidomideMaleMiddle AgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntibodies, MonoclonalBortezomibCalcium Channel BlockersCardiovascular AgentsdaratumumabLenalidomideAdverse eventsCardiovascular drugsMultiple myelomaOverall survivalProgression-free survivalTreatment outcomes

Identifiers

PMID41651961
PMCPMC12946163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.